Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema

PURPOSE: To compare the visual and anatomic outcomes of aflibercept versus ranibizumab as a second line treatment for persistent diabetic macular edema (DME) after initial bevacizumab injections. METHODS: In this retrospective cohort study, patients with center-involved DME of ≥ 300 μm thickness aft...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Ophthalmol
Autors principals: Alsaedi, Nasser G, Alselaimy, Ruba M, Alshamrani, Abdulaziz A, AlAjmi, Muhammed, Khandekar, Rajiv, Al-Dhibi, Hassan, Al-Abdullah, Abdulelah A
Format: Artigo
Idioma:Inglês
Publicat: Dove 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8286127/
https://ncbi.nlm.nih.gov/pubmed/34285463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S316271
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars